Events / Exhibitions

Outline

Date

Wed. 28th May, 2025

Time

8:00 a.m. PDT, 11:00 a.m. EDT

Speaker

Professor Yasuhito Uezono M.D., Ph.D. Department of Pain Control Research, The Jikei University School of Medicine
Naoya Miyashita M.D., Ph.D. Research Fellow of Duke University school of Medicine

Program

1. Distinct microRNA signature and suppression of ZFP36L1 define ASCL1-positive lung adenocarcinoma. (40min.)
   Presented by: Naoya Miyashita: Research Fellow, Duke University school of Medicine
2. Establishment of novel cancer cachexia models that meet the diagnostic criteria of human cachexia: with the 85As2 cancer cells. (40min.)
   Presented by: Yasuhito Uezono: Professor, Department of Pain Control Research, The Jikei University School of Medicine

Registration

Click HERE

Contact

If you have any question, please feel free to contact us: jutaku2@fujifilm.com

Don't miss out on the opportunity to learn more and see how your organization can benefit from JCRB Cell line.

　

Webinar abstract

1. Distinct microRNA signature and suppression of ZFP36L1 define ASCL1-positive lung adenocarcinoma.
[Presented by: Naoya Miyashita: Research Fellow, Duke University school of Medicine]

ASCL1 (achaete-scute complex homolog 1) is a master transcription factor that defines a distinct subgroup of lung adenocarcinoma with unique clinical and molecular characteristics. This subtype, found in approximately 10% of lung adenocarcinomas, exhibits neuroendocrine differentiation and predominantly occurs in current or former smokers, with typically no EGFR mutations. Transcriptome analysis reveals that ASCL1-positive tumors overlap with the proximal-proliferative molecular subtype and are characterized by global DNA hypomethylation. ASCL1 functions as a master transcriptional regulator associated with super-enhancers and is essential for cell proliferation, survival, and cell cycle control.​
The immune landscape of ASCL1-positive tumors displays an "immune desert" phenotype with reduced infiltration of immune cells (CD8+, CD4+, CD20+, FoxP3+ lymphocytes and CD163+ macrophages) and negative PD-L1 expression, suggesting poor response to checkpoint inhibitors. ASCL1 suppresses chemokine secretion, including CCL20, CXCL2, CXCL10, and CXCL16, disrupting immune cell trafficking.​
Additionally, ASCL1-positive tumors exhibit distinct microRNA profiles, including upregulation of miR-375, miR-95-3p, miR-124-3p, and members of the miR-17~92 family. Notably, ASCL1 positively regulates miR-124-3p, which targets ZFP36L1. ASCL1-positive tumors show suppressed ZFP36L1 protein levels, and experimental restoration of ZFP36L1 inhibits cell proliferation, survival, and cell cycle progression through downregulation of genes like E2F1 and SNAI1. This ASCL1-miR-124-3p-ZFP36L1 regulatory axis contributes to the malignant features of this lung adenocarcinoma subtype.​

　

2. Establishment of novel cancer cachexia models that meet the diagnostic criteria of human cachexia: with the 85As2 cancer cells.
[Presented by: Yasuhito Uezono: Professor, Department of Pain Control Research, The Jikei University School of Medicine]

This seminar represents the establishment of an animal model that meets the diagnostic criteria for human cancer cachexia. Cancer cachexia is a wasting syndrome observed in approximately 80% of end-stage cancer patients, including those with gastric, pancreatic, and lung cancers. Despite long-standing research on why cancer progression leads to reduced food intake and significant weight loss, its underlying mechanisms remain unclear. The lack of progress in this field can largely be attributed to the absence of animal and cellular models that accurately reflect the symptoms of human cancer cachexia. We have successfully established an experimental system for cancer cachexia that meets the diagnostic criteria for human cancer cachexia. To this end, we purchased cancer cell lines from a cell bank and selected those that induce cancer cachexia using body weight loss as an indicator. We found the cell line associated with significant body weight loss from 15 stomach cancer cell lines examined. We identified the 85As2 stomach cancer cells that induces both body weight loss, showing a 100% probability of causing body weight loss. The 85As2-inoculated rats, showing severe weight loss and fat mass reduction, met those criteria for human cancer cachexia definition. In the models, leukemia inhibitory factor (LIF), a cytokine involved in various biological processes such as inflammation, cell differentiation, showed a marked increase along with the symptoms of cachexia. We further discussed treatments for cancer cachexia with the 85As2 models, and several potential therapeutics, including ghrelin and its orally available ghrelin agonist anamorelin as well as ghrelin signal enhancing herbal medicine rikkunshito, the Japanese kampo medicine, are considered as treatment of cachexia. In the course of the seminar, we stress that the establishment and use these models that reflect human cancer cachexia is very important to develop ideal therapeutics for cancer cachexia.

　

Summary of the webinar

Title: The Role of Japanese Collection of Research Bioresources (JCRB) Cell Bank

JCRB (Japanese Collection of Research Bioresources) is one of the most comprehensive cell banks providing a wide variety of cell lines to investigators across the globe for basic and applied science, spanning many fields of research.
In this webinar you will learn utilization of JCRB in Research.

　

What you can learn with this webinar

• Biomarker exploration and signaling analysis using JCRB cell lines.
• Novel cell line establishment causing cancer cachexia from JCRB cell lines.
• miRNA analysis on lung cancer research using JCRB cell lines.

　

What is JCRB?

JCRB (Japanese Collection of Research Bioresources) provides one of the most comprehensive cell banks in the world to investigators across the globe for pure and applied science, spanning many fields of research.

Human and animal cell lines from resource centers referred to as cell banks enable in vitro test systems to mimic the physiological state of cells in vivo and give researchers access to consistent, reliable data. We have teamed up with the National Institute of Biomedical Innovation to bring you access to over 1,600 cell lines as the exclusive provider of JCRB's comprehensive catalog of cell lines in Europe.

Cell Bank Features

• Over 1,600 human and animal cell lines
• Human culture cells derived from various pathologies
• Ethnic and gender diversity